Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aurinia Pharmaceuticals

8.21
+0.01000.12%
Post-market: 8.210.00000.00%16:41 EDT
Volume:751.10K
Turnover:6.19M
Market Cap:1.12B
PE:205.25
High:8.38
Open:8.21
Low:8.20
Close:8.20
Loading ...

Corcept (CORT) Soars 13.6%: Is Further Upside Left in the Stock?

Zacks
·
31 Jan

Aurinia (AUPH) Upgraded to Buy: Here's Why

Zacks
·
23 Jan

Exploring Three High Growth Tech Stocks In The United States

Simply Wall St.
·
12 Dec 2024

Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options

Zacks
·
10 Dec 2024

While institutions own 40% of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), retail investors are its largest shareholders with 52% ownership

Simply Wall St.
·
06 Dec 2024

We Might See A Profit From Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Soon

Simply Wall St.
·
03 Dec 2024

Positive Outlook for Aurinia Pharmaceuticals Boosted by Favorable Lupus Nephritis Guidelines

TIPRANKS
·
21 Nov 2024

Aurinia Pharmaceuticals Celebrates New Lupus Nephritis Guidelines

TIPRANKS
·
19 Nov 2024

Aurinia Commends 2024 Updated Acr Guidelines for Screening, Treatment, and Management of Lupus Nephritis

THOMSON REUTERS
·
19 Nov 2024

Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis

Business Wire
·
19 Nov 2024

Aurinia Highlights Lupus Nephritis Breakthroughs at ACR 2024

TIPRANKS
·
15 Nov 2024

Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of Lupkynis® in Managing Ln at American College of Rheumatology Convergence 2024

THOMSON REUTERS
·
15 Nov 2024

Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024

Business Wire
·
15 Nov 2024

RBC Adjusts Aurinia Pharmaceuticals' Price Target to $9 From $8, Keeps Outperform Speculative Risk Rating

MT Newswires Live
·
11 Nov 2024

Aurinia Pharmaceuticals (AUPH) Gets a Buy from RBC Capital

TIPRANKS
·
11 Nov 2024

Positive Outlook on Aurinia Pharmaceuticals Amid Strong Financial Performance and Strategic Cost Management

TIPRANKS
·
11 Nov 2024

Aurinia Pharmaceuticals: Strong Q3 Performance and Promising Outlook Justify Buy Rating

TIPRANKS
·
08 Nov 2024

Aurinia Pharmaceuticals Inc (AUPH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...

GuruFocus.com
·
08 Nov 2024

Aurinia stock jumps 14% on Q3 earnings, restructuring announcement

seekingalpha
·
08 Nov 2024

Aurinia Pharmaceuticals Reports Q3 Beat, Plans to Cut Workforce by 45%; Shares Rise

MT Newswires Live
·
07 Nov 2024